ANNX

Based on Annexon, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.

What does Annexon do?

Annexon is a clinical-stage biopharmaceutical company developing treatments for autoimmune, neurodegenerative, and ophthalmic diseases. Its approach centers on blocking C1q, a molecule that initiates the classical complement pathway, which is implicated in a range of serious conditions including Guillain-Barré syndrome, geographic atrophy, and Huntington's disease.

Does ANNX pay dividends?

No, Annexon does not pay a dividend. As a pre-revenue clinical-stage company, it reinvests all available capital into research and clinical development. Dividend payments are not typical for companies at this stage of development.

When does ANNX report earnings?

Annexon reports on a quarterly cadence, as required for US-listed public companies. Because it has no product revenue, results focus on R&D spending and cash position. Check Annexon's investor relations page for the most current reporting schedule.

Is ANNX a good stock to buy?

UQS Score rates ANNX as Poor overall. Quality, Moat, and Growth are all rated Weak, while Valuation is Elevated — a combination that signals meaningful risk relative to current pricing. The Good Risk rating is a relative positive, but the overall profile warrants careful consideration. View the full analysis on UQS Score.

Is ANNX overvalued?

The UQS Valuation pillar for ANNX is rated Elevated, suggesting the current market price embeds optimistic assumptions about future clinical success. For a pre-revenue biotech, valuation is heavily dependent on pipeline outcomes, which remain uncertain.

How does ANNX compare to its competitors?

Compared to peers like Lexicon Pharmaceuticals, Design Therapeutics, and ARS Pharmaceuticals, Annexon is differentiated by its C1q complement pathway focus spanning multiple disease areas. Each competitor pursues distinct mechanisms and indications, making direct comparisons complex. The full UQS peer comparison is available to Pro members.

What is ANNX's market cap bracket?

Annexon is classified as a small-cap company. This places it in a segment of the market characterized by higher volatility, greater sensitivity to clinical trial outcomes, and more limited access to capital compared to larger biopharmaceutical peers.

Who founded Annexon?

Annexon was incorporated in 2011. Details about the founding team are publicly available through the company's official website and SEC filings, which provide the most accurate and current information about its leadership history.

Is ANNX a long-term quality investment?

From a long-term quality perspective, ANNX currently scores as Poor on the UQS composite. Weak ratings across Quality, Moat, and Growth reflect the absence of commercial products and durable competitive advantages. Long-term quality indicators would need to improve substantially as the pipeline matures. Pro members can track pillar changes over time.

What is the main competitive advantage of Annexon?

Annexon's scientific differentiation lies in its focus on C1q inhibition — a mechanism that sits upstream in the complement cascade and may address both autoimmune and neurodegenerative disease processes. However, the UQS Moat pillar is currently rated Weak, reflecting that this scientific approach has not yet translated into a durable commercial advantage.

What sector does ANNX belong to?

Annexon operates in the Healthcare sector, specifically within clinical-stage biopharmaceuticals. It targets rare and specialty diseases across neurology, hematology, and ophthalmology — areas with significant unmet medical need and, correspondingly, high development risk.

Is ANNX a growth stock or value stock?

Based on UQS pillar labels, ANNX does not fit neatly into either category. Growth is rated Weak due to the absence of near-term revenue, while Valuation is Elevated — meaning the stock is priced for future success rather than current fundamentals. It is best characterized as a speculative clinical-stage biotech.

Annexon, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.

Annexon, Inc. faces growth headwinds with declining or stagnant revenue trends.

Annexon, Inc. maintains a reasonable risk profile with manageable debt levels.

Annexon, Inc. appears expensively valued relative to its fundamentals and growth prospects.

Annexon, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for ANNX.

The UQS (Unified Quality Score) for Annexon, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.

Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.

Moat (25%) assesses Annexon, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.

Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.

Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.

Valuation (15%) measures whether Annexon, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.

Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.